Ocular toxicity of targeted therapies

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3277-3286

  Renouf, Daniel J ^a   Velazquez Martin, Juan P ^a   Simpson, Rand ^a   Siu, Lillian L ^a   Bedard, Philippe L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANASTROZOLE; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; BRIVANIB; CETUXIMAB; CORTICOSTEROID; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EYE DROPS; GEFITINIB; IMATINIB; IPILIMUMAB; LENVATINIB; LINIFANIB; NILOTINIB; NINTEDANIB; ORANTINIB; PAMIDRONIC ACID; PANITUMUMAB; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TAMOXIFEN; VASCULOTROPIN; ZOLEDRONIC ACID;

ADAPTIVE IMMUNITY; BLEPHARITIS; BLURRED VISION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CAPILLARY PERMEABILITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLITIS; COLORECTAL CANCER; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CORNEA EPITHELIUM; CORNEA EROSION; DIABETIC RETINOPATHY; DIPLOPIA; DRUG MEGADOSE; DRUG WITHDRAWAL; DRY EYE; ECTROPION; ENTROPION; EPIPHORA; EPISCLERITIS; EXOPHTHALMOS; EYE IRRITATION; EYE TOXICITY; EYELID EDEMA; GASTROINTESTINAL STROMAL TUMOR; GRAVES DISEASE; HEAD AND NECK CANCER; HEMIANOPIA; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNOLOGICAL TOLERANCE; IRITIS; KERATITIS; KERATOPATHY; KIDNEY CANCER; LACRIMATION DISORDER; LUNG NON SMALL CELL CANCER; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NEUROPATHY; ONCOGENE C KIT; OPTIC NERVE DISEASE; OPTIC NEURITIS; PANCREAS CANCER; PAPILLITIS; PATHOGENESIS; PERIORBITAL EDEMA; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; PIGMENT EPITHELIUM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA VEIN OCCLUSION; RETROLENTAL FIBROPLASIA; REVIEW; SCLERITIS; SIGNAL TRANSDUCTION; THYROID DISEASE; TOXIC EPIDERMAL NECROLYSIS; UVEITIS; VITILIGO; VOGT KOYANAGI SYNDROME;

ANTINEOPLASTIC AGENTS; DRUGS, INVESTIGATIONAL; EYE DISEASES; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84866623276     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.5851     Document Type: Review

References (128)

1. al-Tweigeri T, Nabholtz JM, Mackey JR: Ocular toxicity and cancer chemotherapy: A review. Cancer 78:1359-1373, 1996
2. National Cancer Institute: Common Terminology Criteria for Adverse Events. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm#ctc-40
3. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
5. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007
6. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007
7. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
8. Tullo AB, Esmaeli B, Murray PI, et al: Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in phase I and II clinical trials. Eye (Lond) 19:729-738, 2005
9. Zhang G, Basti S, Jampol LM: Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: Case reports and a review of literature. Cornea 26:858-860, 2007
10. Shahrokni A, Matuszczak J, Rajebi MR, et al: Erlotinib-induced episcleritis in a patient with pancreatic cancer. JOP 9:216-219, 2008
11. Johnson KS, Levin F, Chu DS: Persistent corneal epithelial defect associated with erlotinib treatment. Cornea 28:706-707, 2009
12. Methvin AB, Gausas RE: Newly recognized ocular side effects of erlotinib. Ophthal Plast Reconstr Surg 23:63-65, 2007
13. Burtness B, Anadkat M, Basti S, et al: NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 7:S5-S21, 2009 (suppl 1)
14. Braiteh F, Kurzrock R, Johnson FM: Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 26:3460-3462, 2008
15. Saif MW, Gnanaraj J: Erlotinib-induced trichomegaly in a male patient with pancreatic cancer. Cutan Ocul Toxicol 29:62-66, 2010
16. Márquez G, Herrera-Acosta E, Vidal I, et al: A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva). Int J Dermatol 48:97-98, 2009
17. Dranko S, Kinney C, Ramanathan RK: Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer. Clin Colorectal Cancer 6:224-225, 2006
18. Melichar B, Nemcova I: Eye complications of cetuximab therapy. Eur J Cancer Care (Engl) 16:439-443, 2007
19. Ramírez-Soria MP, Espana-Gregori E, Avino-Martinez J, et al: Blepharitis related to cetuximab treatment in an advanced colorectal cancer patient. Arch Soc Esp Oftalmol 83:665-668, 2008
20. Tonini G, Vincenzi B, Santini D, et al: Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient. J Natl Cancer Inst 97:606-607, 2005
21. Cohen PR, Escudier SM, Kurzrock R: Cetuximab-associated elongation of the eyelashes: Case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. Am J Clin Dermatol 12:63-67, 2011
22. Rodriguez NA, Ascaso FJ: Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer. J Clin Oncol 29:e532-e533, 2011
23. Bambury R, McCaffrey JA: Trichomegaly of the eyelashes after colorectal cancer treatment with the epidermal growth factor receptor inhibitor cetuximab. Clin Colorectal Cancer 8:235, 2009
24. Bouche O, Brixi-Benmansour H, Bertin A, et al: Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 16:1711-1712, 2005
25. Vaccaro M, Pollicino A, Barbuzza O, et al: Trichomegaly of the eyelashes following treatment with cetuximab. Clin Exp Dermatol 34:402-403, 2009
26. Vano-Galvan S, Rios-Buceta L, Ma DL, et al: Cetuximab-induced hypertrichosis of the scalp and eyelashes. J Am Acad Dermatol 62:531-533, 2010
27. Foerster CG, Cursiefen C, Kruse FE: Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea 27:612-614, 2008
28. Specenier P, Koppen C, Vermorken JB: Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy. Ann Oncol 18:961-962, 2007
29. Hecht JR, Patnaik A, Berlin J, et al: Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110:980-988, 2007
30. Giusti RM, Shastri K, Pilaro AM, et al: U.S. Food and Drug Administration approval: Panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 14:1296-1302, 2008
31. Nakamura Y, Sotozono C, Kinoshita S: The epidermal growth factor receptor (EGFR): Role in corneal wound healing and homeostasis. Exp Eye Res 72:511-517, 2001
32. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002
33. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
34. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001
35. Jabbour E, Deininger M, Hochhaus A: Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25:201-210, 2011
36. Esmaeli B, Diba R, Ahmadi MA, et al: Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye (Lond) 18:760-762, 2004
37. Esmaeli B, Prieto VG, Butler CE, et al: Severe periorbital edema secondary to STI571 (Gleevec). Cancer 95:881-887, 2002
38. Dogan SS, Esmaeli B: Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor. Hematol Oncol Clin North Am 23:109-114, 2009
39. Fraunfelder FW, Solomon J, Druker BJ, et al: Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 19:371-375, 2003
40. Govind Babu K, Attili VS, Bapsy PP, et al: Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol 27:43-44, 2007
41. Masood I, Negi A, Dua HS: Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery. J Cataract Refract Surg 31:2427-2428, 2005
42. Pietras K, Ostman A, Sjoquist M, et al: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61:2929-2934, 2001
43. Kaiser-Kupfer MI, Lippman ME: Tamoxifen retinopathy. Cancer Treat Rep 62:315-320, 1978
44. Gianni L, Panzini I, Li S, et al: Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: Results from International Breast Cancer Study Group trials. Cancer 106:505-513, 2006
45. Kaiser-Kupfer MI, Kupfer C, Rodrigues MM: Tamoxifen retinopathy: A clinicopathologic report. Ophthalmology 88:89-93, 1981
46. Flaxel CJ, Mulholland B, Haynes B, et al: Intraocular penetration of tamoxifen. Ophthalmology 107:2006-2009, 2000
47. Toimela T, Salminen L, Tahti H: Effects of tamoxifen, toremifene and chloroquine on the lysosomal enzymes in cultured retinal pigment epithelial cells. Pharmacol Toxicol 83:246-251, 1998
48. Eisner A, Toomey MD, Falardeau J, et al: Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors. Breast Cancer Res Treat 106:161-170, 2007
49. Berenson JR, Hillner BE, Kyle RA, et al: American Society of Clinical Oncology Clinical Practice Guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719-3736, 2002
50. Hillner BE, Ingle JN, Chlebowski RT, et al: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003
51. Basch EM, Somerfield MR, Beer TM, et al: American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol 25:5313-5318, 2007
52. Fraunfelder FW, Fraunfelder FT: Bisphosphonates and ocular inflammation. N Engl J Med 348:1187-1188, 2003
53. Banal F, Briot K, Ayoub G, et al: Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer. J Rheumatol 35:2458-2459, 2008
54. Colucci A, Modorati G, Miserocchi E, et al: Anterior uveitis complicating zoledronic acid infusion. Ocul Immunol Inflamm 17:267-268, 2009
55. El Saghir NS, Otrock ZK, Bleik JH: Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer. BMC Cancer 5:156, 2005
56. Kilickap S, Ozdamar Y, Altundag MK, et al: A case report: Zoledronic acid-induced anterior uveitis. Med Oncol 25:238-240, 2008
57. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
58. US Food and Drug Administration: Medication guide: Yervoy (ipilimumab). http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/125377s0000MedG.pdf
59. Robinson MR, Chan CC, Yang JC, et al: Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis. J Immunother 27:478-479, 2004
60. Du L, Yang P, Hou S, et al: Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome. Clin Immunol 127:43-48, 2008
61. Bristol-Myers Squibb: Package insert: Yervoy (ipilimumab). http://packageinserts.bms.com/pi/pi-yervoy.pdf
62. Attia P, Phan GQ, Maker AV, et al: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043-6053, 2005
63. Borodic G, Hinkle DM, Cia Y: Drug-induced Graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 27:e87-e88, 2011
64. Yanagawa T, Hidaka Y, Guimaraes V, et al: CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 80:41-45, 1995
65. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
66. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
67. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 356:115-124, 2007
68. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
69. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
70. Rini BI, Escudier B, Tomczak P, et al: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 378:1931-1939, 2011
71. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
72. Lieu C, Heymach J, Overman M, et al: Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 17:6130-6139, 2011
73. Wilhelm SM, Dumas J, Adnane L, et al: Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245-255, 2011
74. Tannir NM, Wong YN, Kollmannsberger CK, et al: Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer 47:2706-2714, 2011
75. Lockhart AC, Rothenberg ML, Dupont J, et al: Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28:207-214, 2010
76. Stewart MW: The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc 87:77-88, 2012
77. Michaelides M, Kaines A, Hamilton RD, et al: A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2. Ophthalmology 117:1078-1086, 2010
78. CATT Research Group, Martin DF, Maguire MG, et al: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897-1908, 2011
79. Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al: Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603-615, 2011
80. Demir M, Oba E, Gulkilik G, et al: Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results. Clin Ophthalmol 5:745-749, 2011
81. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113:2002.e1-2002.e12, 2006
82. Fielden M, Nelson B, Kherani A: Acute intraocular inflammation following intravitreal injection of bevacizumab: A large cluster of cases. Acta Ophthalmol 89:e664-e665, 2011
83. Georgopoulos M, Polak K, Prager F, et al: Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 93:457-462, 2009
84. Penha FM, Rodrigues EB, Maia M, et al: Retinal and ocular toxicity in ocular application of drugs and chemicals: Part II - Retinal toxicity of current and new drugs. Ophthalmic Res 44:205-224, 2010
85. Darlow BA, Ells AL, Gilbert CE, et al: Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed [epub ahead of print on December 30, 2011]
86. Eisen T, Sternberg CN, Robert C, et al: Targeted therapies for renal cell carcinoma: Review of adverse event management strategies. J Natl Cancer Inst 104:93-113, 2012
87. Cohen RB, Oudard S: Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities. Invest New Drugs [epub ahead of print on February 12, 2012]
88. Wegner A, Khoramnia R: Neurosensory retinal detachment due to sunitinib treatment. Eye (Lond) 25:1517-1518, 2011
89. Wong TY, Mitchell P: The eye in hypertension. Lancet 369:425-435, 2007
90. Glusker P, Recht L, Lane B: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354:980-982, 2006
91. Cumurciuc R, Martinez-Almoyna L, Henry C, et al: Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev Neurol (Paris) 164:605-607, 2008
92. Messersmith WA, Hidalgo M, Carducci M, et al: Novel targets in solid tumors: MEK inhibitors. Clin Adv Hematol Oncol 4:831-836, 2006
93. Lorusso PM, Adjei AA, Varterasian M, et al: Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23:5281-5293, 2005
94. Rinehart J, Adjei AA, Lorusso PM, et al: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456-4462, 2004
95. LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 16:1924-1937, 2010
96. Huang W, Yang AH, Matsumoto D, et al: PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther 25:519-530, 2009
97. Adjei AA, Cohen RB, Franklin W, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139-2146, 2008
98. Banerji U, Camidge DR, Verheul HM, et al: The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): A phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 16:1613-1623, 2010
99. Tolcher AW, Baird RD, Patnaik A, et al: A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol 29:195s, 2011 (suppl; abstr 3004)
100. Infante JR, Fecher A, Nallapereddy S, et al: Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol 28:204s, 2010 (suppl; abstr 2503)
101. Messersmith WA, Falchook GS, Fecher LA, et al: Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212 in pancreatic and colorectal cancer. J Clin Oncol 29, 2011 (suppl 4; abstr 246)
102. Tolcher AW, Bendell JC, Patnaik A, et al: A phase Ib study of the MEK inhibitor GSK1120212 combined with gemcitabine in patients with solid tumors: Interim results. J Clin Oncol 29, 2011 (suppl 4; abstr 278)
103. Dolly SO, Albanell J, Kraeber-Bodere F, et al: First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors J Clin Oncol 29:195s, 2011 (suppl; abstr 3006)
104. Leijen S, Middleton MR, Tresca P, et al: Phase I (ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced/metastatic solid tumor. J Clin Oncol 29:198s, 2011 (suppl; abstr 3017)
105. Houede N, Faivre SJ, Awada A, et al: Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies. J Clin Oncol 29:198s, 2011 (suppl; abstr 3019)
106. Delord J, Houede N, Awada A, et al: First-in-human phase I safety, pharmacokinetic, and pharmacodynamic analysis of the oral MEK-inhibitor AS703026 (two regimens) in patients with advanced solid tumors. J Clin Oncol 28:205s, 2010 (suppl; abstr 2504)
107. Gore L, Lewis K, Von Hoff DD, et al: Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer. J Clin Oncol 29:195s, 2011 (suppl 15; abstr 3007)
108. Frémin C, Meloche S: From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 3:8, 2010
109. Shapiro G, LoRusso P, Kwak EL, et al: Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. J Clin Oncol 29:195s, 2011 (suppl; abstr 3005)
110. Gemenetzi M, De Salvo G, Lotery AJ: Central serous chorioretinopathy: An update on pathogenesis and treatment. Eye (Lond) 24:1743-1756, 2010
111. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
112. Gambacorti-Passerini C, Messa C, Pogliani EM: Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 364:775-776, 2011
113. Samuel TA, Sessa C, Britten C, et al: AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies. J Clin Oncol 28:211s, 2010 (suppl; abstr 2528)
114. Shapiro G, Kwak E, Dezube B, et al: Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors. J Clin Oncol 28:250s, 2010 (suppl; abstr 3069)
115. Solit DB, Ivy SP, Kopil C, et al: Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13:1775-1782, 2007
116. Shome D, Trent J, Espandar L, et al: Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. Ophthalmology 115:483-487, 2008
117. Yap TA, Yan L, Patnaik A, et al: First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29:4688-4695, 2011
118. Burris HA, Siu LL, Infante JR, et al: Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. J Clin Oncol 29:194s, 2011 (suppl 15; abstr 3003)
119. Kurzrock R, Patnaik A, Rosenstein L, et al: Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). J Clin Oncol 29:215s, 2011 (suppl; abstr 3085)
120. Limentani SA, Burris H, Anderson AP, et al: A phase I dose-escalation and pharmacokinetic (PK) evaluation of an oral AKT inhibitor, LY2503029 (LY). J Clin Oncol 2011 (suppl; abstr e13575)
121. Antisoma: Welcome to Antisoma. http://www.antisoma.com/asm/media/press/ pr2010/2010-03-29/
122. Jameson MB, Thompson PI, Baguley BC, et al: Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88:1844-1850, 2003
123. Rustin GJ, Bradley C, Galbraith S, et al: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study. Br J Cancer 88:1160-1167, 2003
124. Jameson MB, Sharp DM, Sissingh JI, et al: Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials. Invest Ophthalmol Vis Sci 50:2553-2559, 2009
125. McKeage MJ, Fong P, Jeffery M, et al: 5,6-dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: A phase I safety study of a vascular disrupting agent. Clin Cancer Res 12:1776-1784, 2006
126. Zweifel M, Patterson DM, Padhani AR, et al: Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors. J Clin Oncol 28:227s, 2010 (suppl; abstr 2594)
127. Advani R, Forero-Torres A, Furman RR, et al: Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 27:4371-4377, 2009
128. Bourcier T, De Saint-Jean M, Brignole F, et al: Expression of CD40 and CD40 ligand in the human conjunctival epithelium. Invest Ophthalmol Vis Sci 41:120-126, 2000